PharmaCyte Biotech (PMCB) vs Propanc Biopharma (PPCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Propanc Biopharma is the larger company by market cap ($4.6 million vs $4.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PMCB | PPCB |
|---|---|---|
| Share price | $0.3974 | $0.471 |
| Market cap | $4.27M | $4.63M |
| 1-day change | -2.02% | -5.55% |
| EPS (TTM) | $-2.31 | $-17.62 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.51 | $47.50 |
| 52-week low | $0.3339 | $0.46 |
| Distance from 52-week high | -73.68% | -99.01% |
| Average volume | 205.72K | 1.79M |
| Shares outstanding | 10.74M | 9.83M |
| Employees | 2 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 2 employees
About Propanc Biopharma
PPCB stock →Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
PMCB vs PPCB FAQ
Which is bigger, PharmaCyte Biotech or Propanc Biopharma?
Propanc Biopharma (PPCB) is larger, with a market capitalization of $4.63M compared with $4.27M for PharmaCyte Biotech (PMCB).
Are PharmaCyte Biotech and Propanc Biopharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for PharmaCyte Biotech and Biotechnology: Pharmaceutical Preparations for Propanc Biopharma.